Published in Onkologie on February 01, 1991
The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet (1996) 4.59
The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. Stat Med (1999) 3.53
Prognostic implications of monosomy 3 in uveal melanoma. Lancet (1996) 3.26
The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. Nat Genet (1996) 3.05
Fraud in medical research: an international survey of biostatisticians. ISCB Subcommittee on Fraud. Control Clin Trials (2000) 2.67
Risk from low-dose exposures. Science (1994) 1.99
Eocene Patagonia fossils of the daisy family. Science (2010) 1.77
Pleural effusions: a new negative prognostic parameter for acute pancreatitis. Am J Gastroenterol (1994) 1.61
Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol (1993) 1.60
Chromosomal gains and losses in uveal melanomas detected by comparative genomic hybridization. Cancer Res (1994) 1.57
Improvement of immune functions in HIV infection by sulfur supplementation: two randomized trials. J Mol Med (Berl) (2000) 1.50
Unalarmed interruption of continuous drug infusion by Perfusor Space GC syringe pumps. Anaesthesia (2013) 1.39
Nonrandom chromosomal abnormalities in primary uveal melanoma. J Natl Cancer Inst (1990) 1.35
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer (2007) 1.33
Modeling cancer detection: tumor size as a source of information on unobservable stages of carcinogenesis. Math Biosci (2001) 1.30
Preliminary Phytochemical Screening and Antimicrobial Studies of Lantana indica Roxb. Indian J Pharm Sci (2010) 1.26
A ninth complementation group in xeroderma pigmentosum, XP I. Mutat Res (1985) 1.26
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol (2005) 1.22
Cytogenetics of twelve cases of uveal melanoma and patterns of nonrandom anomalies and isochromosome formation. Cancer Genet Cytogenet (1995) 1.17
Importance of size and composition of particles for effects on cells in vitro. Inhal Toxicol (2007) 1.15
Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer: a phase II trial. Eur J Cancer (2002) 1.11
Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. J Clin Oncol (1996) 1.10
The extracellular matrix in hepatic regeneration. Localization of collagen types I, III, IV, laminin, and fibronectin. Lab Invest (1991) 1.09
Ligand/receptor binding for 2,3,7,8-TCDD: implications for risk assessment. Fundam Appl Toxicol (1993) 1.08
Spontaneous in vitro malignant transformation in a xeroderma pigmentosum fibroblast line. Int J Cancer (1983) 1.08
[Intra-operative drop in sevoflurane and oxygen concentrations. Leakage of the ventilation system]. Anaesthesist (2009) 1.08
A new dhfrVIII trimethoprim-resistance gene, flanked by IS26, whose product is remote from other dihydrofolate reductases in parsimony analysis. Gene (1995) 1.07
[Chemotherapy in advanced sarcomas (author's transl)]. Dtsch Med Wochenschr (1981) 1.07
Evaluation of historical control data in carcinogenicity studies. Hum Exp Toxicol (2003) 1.06
Duplication and functional divergence in the chalcone synthase gene family of Asteraceae: evolution with substrate change and catalytic simplification. Proc Natl Acad Sci U S A (1996) 1.05
p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res (2001) 1.05
Carcinogenicity of antineoplastic agents in man. Cancer Treat Rev (1984) 1.04
Metaphase and interphase cytogenetics with Alu-PCR-amplified yeast artificial chromosome clones containing the BCR gene and the protooncogenes c-raf-1, c-fms, and c-erbB-2. Cancer Res (1992) 1.02
Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. Pharmacogenetics (2001) 1.00
Effect of glutathione depletion and oral N-acetyl-cysteine treatment on CD4+ and CD8+ cells. FASEB J (1994) 1.00
Dose-response analysis of the enhancement of liver tumour formation in CF-1 mice by dieldrin. Carcinogenesis (1982) 0.99
Modeling the number and size of hepatic focal lesions following exposure to 2,3,7,8-TCDD. Toxicol Appl Pharmacol (1996) 0.99
A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. Br J Cancer (1996) 0.99
Risk characterisation of chemicals in food and diet. Food Chem Toxicol (2003) 0.99
Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs (2010) 0.98
A high-resolution study of chromosome changes in a human prostatic carcinoma cell line (LNCaP). Cancer Genet Cytogenet (1984) 0.98
Elimination of beta-hexachlorocyclohexane in occupationally exposed persons. J Toxicol Environ Health (1997) 0.97
Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study. Onkologie (2005) 0.97
Etoposide and etoposide-ifosfamide therapy for refractory testicular tumors. Cancer Treat Rev (1982) 0.97
Clinical symptoms and DNA repair characteristics of xeroderma pigmentosum patients from Germany. Cancer Res (1991) 0.97
Corticosteroid-induced chemotherapy resistance in urological cancers. Cancer Biol Ther (2006) 0.97
Detection of chromosomal DNA gains and losses in testicular germ cell tumors by comparative genomic hybridization. Genes Chromosomes Cancer (1996) 0.96
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer (2010) 0.96
Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol (2004) 0.95
Phase II study of mitozolomide (M & B 39,565) in colorectal and breast cancer. Invest New Drugs (1988) 0.94
Peripheral neuropathy and ophthalmologic toxicity after treatment with cis-dichlorodiaminoplatinum II. J Cancer Res Clin Oncol (1980) 0.94
Xeroderma pigmentosum patients from Germany: clinical symptoms and DNA repair characteristics. Arch Dermatol Res (1982) 0.94
Chromosome changes in soft tissue sarcomas. J Natl Cancer Inst (1984) 0.93
A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. The Granisetron Study Group. Eur J Cancer (1994) 0.93
Two subclones in a case of uveal melanoma. Relevance of monosomy 3 and multiplication of chromosome 8q. Cancer Genet Cytogenet (1994) 0.92
[Lymphocyte in chronic lymphatic leukemia]. Blut (1975) 0.92
The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res (1995) 0.92
Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood (1990) 0.92
R factor elimination by inhibitors of thymidylate synthetase (fluorodeoxyuridine and showdomycin) and the occurrence of single strand breaks in plasmid DNA. Mol Gen Genet (1974) 0.91
Loss of chromosome 3 alleles and multiplication of chromosome 8 alleles in uveal melanoma. Genes Chromosomes Cancer (1992) 0.91
Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia. Br J Haematol (1993) 0.91
Mineral particles of varying composition induce differential chemokine release from epithelial lung cells: importance of physico-chemical characteristics. Ann Occup Hyg (2005) 0.90
Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapy. Cancer Lett (2005) 0.90
Two-stage models of carcinogenesis, classification of agents, and design of experiments. Fundam Appl Toxicol (1990) 0.90
Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society. Clin Cancer Res (1999) 0.89
Chromosomal aberrations defining uveal melanoma of poor prognosis. Lancet (1992) 0.89
Glutathione-S-transferase M1, M3, T1 and P1 polymorphisms and susceptibility to non-small-cell lung cancer subtypes and hamartomas. Pharmacogenetics (2001) 0.89
Nonrandom chromosome changes in malignant melanoma. Cancer Res (1983) 0.87
Gradient centrifugation analysis of steroid-hormone binding in human malignant melanoma. Anticancer Res (1983) 0.87
Risk assessment of substances that are both genotoxic and carcinogenic report of an International Conference organized by EFSA and WHO with support of ILSI Europe. Food Chem Toxicol (2006) 0.86
Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer. Int J Cancer (1984) 0.86
Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study. J Clin Oncol (1990) 0.86
Impaired recirculation of B lymphocytes in chronic lymphocytic leukemia. Eur J Immunol (1973) 0.86
Circulating hepatitis B virus nucleic acids in chronic infection : representation of differently polyadenylated viral transcripts during progression to nonreplicative stages. Clin Cancer Res (2001) 0.85
[Long-term treatment with "Anovlar" of inbred mice affected with breast cancer]. Arch Geschwulstforsch (1967) 0.85
Immunologic findings in workers formerly exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin and its congeners. Environ Health Perspect (1998) 0.85
Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate. Cancer (1984) 0.85
Age and biogeography of major clades in Liliales. Am J Bot (2001) 0.85
Vinorelbine (Navelbine) in the treatment of breast cancer: the European experience. Semin Oncol (1995) 0.85
Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. Eur J Cancer Clin Oncol (1986) 0.84
The pregnancy-specific glycoprotein family of the immunoglobulin superfamily: identification of new members and estimation of family size. Genomics (1992) 0.84
XP patients from Germany: correlation of colony-forming ability, unscheduled DNA synthesis and single-strand breaks after UV damage in xeroderma pigmentosum fibroblasts. J Cancer Res Clin Oncol (1982) 0.84
DNA of adeno-associated virus (AAV) in testicular tissue and in abnormal semen samples. Hum Reprod (2001) 0.84
Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOG. Leuk Lymphoma (1996) 0.84
Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer (2006) 0.84
High-dose epirubicin + cyclophosphamide (HD-EC) in metastatic breast cancer: a dose-finding study. Onkologie (1988) 0.84
Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukaemia. Br J Haematol (1992) 0.83
Regulation of CCSP (PCB-BP/uteroglobin) expression in primary cultures of lung cells: involvement of C/EBP. DNA Cell Biol (1998) 0.83
Prognostic impact of interferon alpha-induced cytogenetic remission in chronic myelogenous leukaemia: long-term follow-up. Eur J Haematol (1996) 0.83
Low plasma glutamine in combination with high glutamate levels indicate risk for loss of body cell mass in healthy individuals: the effect of N-acetyl-cysteine. J Mol Med (Berl) (1996) 0.83
Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group. Breast Cancer Res Treat (1999) 0.83
The significance of trisomy 8 in de novo acute myeloid leukaemia: the accompanying chromosome aberrations determine the prognosis. German AML Cooperative Study Group. Br J Haematol (1997) 0.83
A two-sample censored-data rank test for acceleration. Biometrics (1984) 0.83
Effect of carnitine on muscular glutamate uptake and intramuscular glutathione in malignant diseases. Br J Cancer (2000) 0.83
[Levonantradol in the treatment of nausea and vomiting caused by cytostatic drugs (author's transl) clinical studies]. Dtsch Med Wochenschr (1982) 0.83
Tumor necrosis factor in advanced colorectal cancer: a phase II study. A trial of the phase I/II study group of the Association for Medical Oncology of the German Cancer Society. Onkologie (1990) 0.82
[Diabetes mellitus and breast cancer. A retrospective follow-up study]. Onkologie (1990) 0.82